Here are relevant reports on : herbal-medicine-market
-
Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, stood at US$145.53 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$246.66 billion by the end of the period. Factors such as the growing integration of AI and ML to enhance precision diagnostics and medicine development supported by rising collaborations between pharmaceutical and diagnostics companies to improve precision healthcare and the rise in direct-to-consumer testing are driving the growth in the market.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
The global cell line development market is expected to reach 3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.
- Published: September 2014
- Price: $ 4950
- TOC Available:
-
European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Thyroid, Cardiology), Procedures - Forecasts to 2020
Over the years, the European nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The European radiopharmaceuticals market is witnessing growth owing to an increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 radioisotopes are estimated to contribute the highest to the European nuclear medicine diagnostic market in 2015, whereas Ra-223, I-131 and Y-90 ensured their leading position in the therapeutic market. The European nuclear medicine/radiopharmaceuticals market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, growing at a CAGR of 8.2% from 2015 to 2020.
- Published: November 2015
- Price: $ 4950
- TOC Available:
-
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) - Global Forecast to 2027
The global digital pharmacy market growth is primed to transition from USD 96.5 billion in 2022 to USD 211.9 billion by 2027, showcasing a strong CAGR of 17.0%. Key drivers include the rising consumer preference for online medicine purchases, especially during and after the COVID-19 pandemic, market consolidations, and the aging population.
- Published: June 2022
- Price: $ 4950
- TOC Available:
-
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030
The global molecular cytogenetics market, valued at US$0.97 billion in 2024, stood at US$1.02 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2030, culminating in a forecasted valuation of US$1.43 billion by the end of the period. The market growth is fueled by increasing incidence of cancer & genetic disorders and rising usage of molecular cytogenetics in clinical pathology testing.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Europe Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, RPM, Immunotherapy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The Europe artificial intelligence (AI) in healthcare market is projected to reach USD 31.72 billion by 2030 from USD 6.12 billion in 2025, at a CAGR of 39.0% during the forecast period. The prominent players operating in the Europe artificial intelligence (AI) in healthcare market include Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), Epic Systems Corporation (US), GE Healthcare (US), Medtronic (US), Oracle (US), Merative (IBM) (US), Google (US), Cognizant (US), Johnson & Johnson (US), and Amazon Web Services, Inc. (US), among others. These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, mergers, and acquisitions to strengthen their market presence in the Europe artificial intelligence (AI) in healthcare market.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029
The global human organoids market, valued at US$1.07 billion in 2023, stood at US$1.19 billion in 2024 and is projected to advance at a resilient CAGR of 14.4% from 2024 to 2029, culminating in a forecasted valuation of US$2.33 billion by the end of the period. The main factor driving this market is the rising demand for organoids in drug testing, as they provide more reliable results than conventional 2D cell cultures.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Advanced Visualization Market by Type (Enterprise, Standalone), Modality (MRI, CT, PET, Ultrasound, Radiotherapy, Nuclear Medicine), Application (Radiology, Oncology, Neuro), End User (Hospital, ASC, Diagnostic Center) & Region - Global Forecast to 2029
The global advanced visualization market, valued at US$3.36 billion in 2023, stood at US$3.78 billion in 2024 and is projected to advance at a resilient CAGR of 11.7% from 2024 to 2029, culminating in a forecasted valuation of US$6.55 billion by the end of the period. Technological advancements in advanced visualization tools, the rising need for early detection of diseases, and the growing support from government & private organizations are key factors driving the market growth.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Precision Medicine Software Market by Delivery Mode (On-Premise & Cloud-Based), End User (Healthcare Providers, Research Centers & Government Institutes, Pharmaceutical & Biotechnology Companies), Application, and Region - Global Forecast to 2024
The precision medicine software market is projected to reach USD 2.0 billion by 2024, at a CAGR of 11.5%. Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market. However, the high cost of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the dearth of skilled IT professionals in healthcare are expected to restrain market growth to a certain extent in the coming years. Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands)
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma), & Region - Global Forecast to 2030
The global AI in oncology market, valued at US$1.92 billion in 2023, stood at US$2.45 billion in 2024 and is projected to advance at a resilient CAGR of 29.4% from 2024 to 2030, culminating in a forecasted valuation of US$11.52 billion by the end of the period. The AI in oncology market is experiencing significant growth due to rising investments in the pharmaceutical and biotech companies to develop potential and advance cancer drugs to reduce the growing cancer burden worldwide.
- Published: December 2024
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
